Mesoblast Limited
MEOBF
$1.35
-$0.62-31.30%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.20M | 11.43M | 5.67M | 5.79M | 5.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.20M | 11.43M | 5.67M | 5.79M | 5.90M |
| Cost of Revenue | 39.94M | 32.62M | 25.31M | 32.51M | 39.72M |
| Gross Profit | -22.74M | -21.19M | -19.64M | -26.73M | -33.81M |
| SG&A Expenses | 39.31M | 35.00M | 30.69M | 27.83M | 24.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 395.00K | 259.50K | 124.00K | -349.00K | -822.00K |
| Total Operating Expenses | 79.64M | 68.34M | 57.04M | 60.46M | 63.87M |
| Operating Income | -62.44M | -56.91M | -51.37M | -54.67M | -57.97M |
| Income Before Tax | -101.81M | -102.52M | -103.23M | -95.69M | -88.15M |
| Income Tax Expenses | 330.00K | 226.50K | 123.00K | -34.00K | -191.00K |
| Earnings from Continuing Operations | -102.14 | -102.75 | -103.35 | -95.65 | -87.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -102.14M | -102.75M | -103.35M | -95.65M | -87.96M |
| EBIT | -62.44M | -56.91M | -51.37M | -54.67M | -57.97M |
| EBITDA | -58.18M | -53.80M | -49.43M | -52.75M | -56.08M |
| EPS Basic | -0.08 | -0.09 | -0.09 | -0.09 | -0.09 |
| Normalized Basic EPS | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 |
| EPS Diluted | -0.08 | -0.09 | -0.09 | -0.09 | -0.09 |
| Normalized Diluted EPS | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 |
| Average Basic Shares Outstanding | 4.83B | 4.66B | 4.48B | 4.21B | 3.95B |
| Average Diluted Shares Outstanding | 4.83B | 4.66B | 4.48B | 4.21B | 3.95B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |